Hematology

Mustang Bio plans to file an IND and start a phase 1 clinical trial as soon as a lead construct is identified.

Investigators sought to understand the mechanisms of transferred T cell proliferation and expression.

Jennifer Buell, PhD, president and chief operating officer of Agenus, discussed the VISION platform the company uses to develop therapies.

Krina K. Patel, MD, MSc, discussed moving away from chemotherapy and toward immunotherapy.

Kevin Heller, MD, executive vice president of research, Jasper Therapeutics, discussed future research with JSP191.

Julie Vose, MD, professor of internal medicine and division chief, Division of Oncology and Hematology, University of Nebraska Medical Center, discussed the use of CAR T-cell therapy in non-Hodgkin lymphoma.

The ongoing phase 1 UNIVERSAL trial has demonstrated an overall response rate of 60% among 10 patients.

The chair of the Lymphoma Group at Mayo Clinic discussed incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.

The professor from the University of Texas Anderson Cancer Center discussed challenges surrounding CAR T-cell therapy for the treatment of follicular lymphoma and other lymphomas.

The professor and chief, of oncology and hematology at University of Nebraska Medical Center discussed research with CAR T therapy in lymphoma.

The lymphoma specialist from Moffitt Cancer Center discussed the advantages of CAR T-cell therapy in non-Hodgkin lymphoma.

David G. Maloney, MD, PhD, covered the importance of standardized criteria in managing CRS and ICANS with CAR T therapy.

The World Federation of Hemophilia’s registry will include long-term safety and efficacy data in people with hemophilia treated with gene therapies.

The professor of clinical medicine, director, Multiple Myeloma and Amyloidosis Program, New York-Presbyterian Hospital, discussed utility of cellular therapies in multiple myeloma.

Experts discuss the use and selection of CAR T therapies in relapsed/refractory diffuse large B-cell lymphoma.

Parexel cell and gene therapy director Izaskun Elorza, MD, shares key factors for industry to consider as this emerging field becomes more prominent.

The hematologic oncologist from Memorial Sloan Kettering Cancer Center discussed factors to consider in selecting CAR T-cell therapies.

Noa Biran, MD, discusses exciting new agents in the field that may fulfill unmet patient needs.

The Regional Care Network Medical Site Director at Memorial Sloan Kettering Cancer Center Basking Ridge discussed patient factors to consider when selecting treatment in R/R MCL.

The associate member in the Department of Malignant Hematology at Moffitt Cancer Center discussed results of the ZUMA-3 trial.

CAR T-cell therapy showed promising results in acute myeloid leukemia at ASCO 2021.

The inaugural leader of the Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center, University of Miami discussed exciting novel therapeutic approaches in multiple myeloma.

Jan Philipp Bewersdorf, MD, hospital resident at Yale University School of Medicine discussed the safety and efficacy of allogeneic hematopoietic stem cell transplant in myelofibrosis.

No concerning effects to liver health were observed in the phase 1/2a study.

The hematologic oncologist from Memorial Sloan Kettering Cancer Center discussed emerging CAR T-cell therapies in hematologic malignancies.